TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26650227
Drug: BI 847325
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 847325 (Schedule A, 2 weeks on, 1 week off, starting at 6 mg, MTD 120 mg/day)
Study: 26650227
Drug: BI 847325
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 847325 (Schedule B, three periods of 5 days on, 2 days off, MTD 150 mg/day)
Study: 26652184
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccination combined with low-dose cyclophosphamide
Study: 26653754
Drug: Opioid substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid substitution therapy
Study: 26654630
Drug: Plasma exchange/plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma exchange/plasma infusion
Study: 26655846
Drug: PF-03446962 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03446962 (10 mg/kg, recommended phase II dose 7 mg/kg)
Study: 26655846
Drug: PF-03446962 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03446962 (0.5 to 15 mg/kg)
Study: 26656277
Drug: QLT091001 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLT091001 (40 mg/m2/day for 7 days)
Study: 26656373
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Shapiro score with PCT levels
Study: 26656373
Drug: Shapiro score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shapiro score ≥4 or PCT > 0.1 μg/L
Study: 26656373
Drug: Shapiro score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shapiro score ≥3 or PCT >0.25 μg/L
Study: 26663671
Drug: Automatic Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic Stimulation Mode (AutoStim) of the Model 106 Vagus Nerve Stimulation (VNS) Therapy System
Study: 26663719
Drug: Docetaxel 40
Normalized name: docetaxel 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 40 mg/m² for Category 1 patients
Study: 26663719
Drug: Docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m² for Category 2 patients
Study: 26663719
Drug: Docetaxel 20
Normalized name: docetaxel 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 20 mg/m² for Category 3 patients
Study: 26666244
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg p.o. BID and cetuximab 250 mg/m(2) weekly following a 400 mg/m(2) load
Study: 26666244
Drug: Selumetinib and
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib and cetuximab combination
Study: 26666256
Drug: New and
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New and more effective diagnostic procedures and targeted therapies against ACC
Study: 26666942
Drug: Artemether-lumefantrine (six-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (six-dose regimen)
Study: 26667382
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of varenicline in combination with smoking cessation counseling
Study: 26668134
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus low-dose dexamethasone (LenDex)
Study: 26668712
Drug: Single-dose 13-valent
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 13-valent pneumococcal conjugate vaccine (PCV13)
Study: 26670630
Drug: Second PDT
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second PDT treatment
Study: 26670630
Drug: High-density subthreshold
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density subthreshold diode micropulse laser (HSML) therapy
Study: 26670630
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment strategy (PDT + HSML)
Study: 26670630
Drug: First half-dose
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First half-dose PDT treatment
Study: 26672094
Drug: Isoglycemic intravenous
Normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoglycemic intravenous glucose infusion
Study: 26672987
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation (1.9 g/d EPA and 1.5 g/d DHA for six weeks)
Study: 26674132
Drug: Combination immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immunotherapy trial utilizing MEDI4736 and MEDI0680
Study: 26674520
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg simvastatin daily for one year
Study: 26674763
Drug: Controlled phytoene
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled phytoene diet (1-5 mg/d) for 42 days, with 3.2 mg (13)C-phytoene consumed on day 14.
Study: 26675348
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human IL-7 (rhIL-7) administered as 3 subcutaneous doses per week.
Study: 26675348
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site reactions and hypersensitivity reaction to IL-7.
Study: 26675779
Drug: Mothers taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers taking vitamin D supplements
Study: 26675779
Drug: Infant daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant daily intake through breast milk of vitamin D
Study: 26676711
Drug: Nonoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative management (24 hours inpatient observation with IV antibiotics, followed by 10 days of oral antibiotics)
Study: 26678646
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (varied by physician discretion)
Study: 26678860
Drug: Weighted combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weighted combination of symptom domains and endoscopic attributes
Study: 26681111
Drug: HYD 20-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYD 20-120 mg daily
Study: 26681676
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/day until progression or intolerance
Study: 26681756
Drug: PZ-128 (0.01-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ-128 (0.01-2 mg/kg) administered by 1 to 2 hours continuous intravenous infusion
Study: 26681756
Drug: PZ-128 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ-128 (0.5 mg/kg) with aspirin
Study: 26681756
Drug: PZ-128 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ-128 (0.5 mg/kg)
Study: 26682038
Drug: Sublingual allergy
Normalized name: Callergy Clear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual allergy immunotherapy tablet (GRAZAX®) plus standard treatment
Study: 26682038
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus standard treatment
Study: 26684198
Drug: Radiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and concomitant-adjuvant temozolomide chemotherapy
Study: 26685770
Drug: Cyclophosphamide 50
Normalized name: cyclophosphamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 50 mg/kg
Study: 26685770
Drug: Cyclophosphamide 100
Normalized name: cyclophosphamide 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 100 mg/kg
Study: 26686256
Drug: Thalidomide at
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide at a starting dose of 50 mg/day, increased by 50 mg/day increments every 4 weeks up to a maximum of 200 mg/day if no response was seen.
Study: 26687423
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m² once a day for days 1-5 of each 28-day cycle and lenalidomide (initially 50 mg for 10 days, later adjusted to 25 mg for 5 days)
Study: 26687423
Drug: Azacitidine and
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine and lenalidomide combination
Study: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 1 (2.5 mCi/m²)
Study: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 2 (5.0 mCi/m²)
Study: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 3 (7.5 mCi/m²)
Study: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 4 (10.0 mCi/m²)
Study: 26687958
Drug: Romidepsin 12
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 12 mg/m(2) combined with CHOP (intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) [maximum 2 mg], oral prednisone 40 mg/m(2))
Study: 26687958
Drug: Romidepsin 10
Normalized name: romidepsin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romidepsin 10 mg/m(2) combined with CHOP
Study: 26687958
Drug: Romidepsin 8
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 8 mg/m(2) combined with CHOP
Study: 26687958
Drug: Romidepsin 12
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 12 mg/m(2) combined with CHOP
Study: 26688485
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg oral three times a week and bortezomib 1.3 mg/m² intravenous two times a week for 2 of 3 weeks for up to eight cycles.
Study: 26688485
Drug: Panobinostat and
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat and bortezomib combination treatment
Study: 26688487
Drug: PF-04449913 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 at 80 mg
Study: 26688487
Drug: PF-04449913 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 at 600 mg
Study: 26688487
Drug: PF-04449913 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 (all doses)
Study: 26688487
Drug: PF-04449913 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04449913 at MTD (400 mg)
Study: 26688487
Drug: Recommended phase
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended phase 2 dose
Study: 26688734
Drug: Walnut-included diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-included diet (56 g providing 366 kcal per day)
Study: 26693035
Drug: Enhanced External
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced External Counterpulsation (EECP) therapy, 260 mm Hg pressure, 60 minutes, 5 days a week for 7 weeks (35 sessions)
Study: 26695065
Drug: Gadofosveset trisodium
Normalized name: Gadofosveset Trisodium
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadofosveset trisodium injection using a dual-injection protocol (70% bolus / 30% slow infusion)
Study: 26695065
Drug: Gadofosveset trisodium
Normalized name: Gadofosveset Trisodium
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadofosveset trisodium injection using a dual-injection protocol (60% bolus / 40% slow infusion)
Study: 26695065
Drug: Gadofosveset injection
Normalized name: gadofosveset
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadofosveset injection optimized for lowest intravascular T1 time
Study: 26698306
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of breath biomarkers with chest CT
Study: 26698868
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) at doses of up to 300 mg/m(2) over 4 hours
Study: 26698868
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) of nab-paclitaxel over 1 hour
Study: 26698868
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) of nab-paclitaxel
Study: 26700485
Drug: TSH-suppressive LT4
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TSH-suppressive LT4 doses
Study: 26700485
Drug: LT4 replacement
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 replacement therapy
Study: 26701919
Drug: Implant-supported therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported therapy
Study: 26702094
Drug: VRC01 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (single dose) in ART-untreated subjects
Study: 26702094
Drug: VRC01 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (two infusions) in ART-treated subjects
Study: 26702094
Drug: VRC01 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (single dose) in ART-untreated subjects with plasma virus load <1000 copies/ml
Study: 26702094
Drug: VRC01 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (single dose) in ART-untreated subjects with baseline virus loads between 3000 and 30,000 copies
Study: 26704148
Drug: Simeprevir 150
Normalized name: simeprevir 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks
Study: 26704626
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg/day for 4 weeks
Study: 26706103
Drug: (177)Lu-girentuximab, 2405
Approvals — FDA: no, EMA: no, PMDA: no
Description: (177)Lu-girentuximab, 2405 MBq/m(2) intravenously, with retreatment after 3 months at 75% of the previous dose if no persistent toxicity or progressive disease.
Study: 26706294
Drug: Three-injection intralymphatic
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-injection intralymphatic immunotherapy
Study: 26708155
Drug: Alectinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 600 mg orally twice daily until progression, death, or withdrawal.
Study: 26708830
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR monotherapy for up to 16 weeks
Study: 26709883
Drug: HBV immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV immunoglobulin and complete vaccine
Study: 26709883
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (lamivudine or tenofovir/emtricitabine) during pregnancy
Study: 26709883
Drug: Incomplete vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete vaccine
Study: 26710961
Drug: Lorazepam (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (one or two doses)
Study: 26710961
Drug: Lorazepam (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (second double dose)
Study: 26711546
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation (CR) prescription at discharge
Study: 26711747
Drug: ABT-493 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-493 (doses ranging from 100 mg to 700 mg)
Study: 26711747
Drug: ABT-530 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-530 (doses of ≥ 40 mg)
Study: 26711756
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g Azithromycin (AZI) given during labor
Study: 26711775
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g doripenem every 8 h
Study: 26711777
Drug: AFN-1252, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFN-1252, 200 mg given by mouth twice daily
Study: 26712084
Drug: pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 10 mg/kg
Study: 26712084
Drug: pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 2 mg/kg (in patients with at least 50% PD-L1 expression)
Study: 26712084
Drug: pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: pembrolizumab 10 mg/kg (in patients with at least 50% PD-L1 expression)
Study: 26712327
Drug: Expensive biologic
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expensive biologic drug
Study: 26715442
Drug: Chemotherapy-related toxicities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-related toxicities (severe neutropenia grades ≥3)
Study: 26715442
Drug: Chemotherapy-related toxicities
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-related toxicities (fatigue grades ≥3)
Study: 26715447
Drug: 6-month guided
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month guided weight loss intervention (twice weekly classes and text messaging)
Study: 26715573
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg orally daily, gemcitabine 1000 mg/m2 intravenously on days 1, 8, 15, and capecitabine 850 mg/m2 orally twice daily on days 1-21.
Study: 26715573
Drug: Vandetanib 200
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vandetanib 200 mg orally daily (during dose escalation phase).
Study: 26715573
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of gemcitabine, capecitabine, and vandetanib.
Study: 26717526
Drug: Citalopram at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram at a dose of 20-60 mg/d for 12 weeks
Study: 26717906
Drug: Tablet-based e-workbook
Normalized name: vitamin E Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based e-workbook for child mental health treatment
Study: 26718090
Drug: Conservative oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative oxygen therapy (target SpO2 88-92% using the lowest FiO2)
Study: 26718690
Drug: Seroprevalence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seroprevalence of pertussis antibodies
Study: 31316836
Drug: Gum Arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum Arabic (GA) 30 g/day for 12 weeks
Study: 26719818
Drug: Biomarker combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker combinations (urinary neutrophil gelatinase lipocalin (NGAL), kidney injury molecule-1 (KIM-1), liver-type fatty acid binding protein (l-FABP), interleukin-18 (IL-18))
Study: 26720423
Drug: Erlotinib 150
Normalized name: erlotinib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 150 mg/d orally until disease progression, with continuation at discretion after progression.
Study: 26720423
Drug: Erlotinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib therapy overall.
Study: 26720423
Drug: Erlotinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib therapy in safety population (n = 207).
Study: 26723501
Drug: Olaparib 400mg
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 400mg bid capsule monotherapy
Study: 26724322
Drug: B Cell
Normalized name: B cell antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: B Cell Depletion Therapy
Study: 26725920
Drug: PA32540 (enteric-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg)
Study: 26729345
Drug: Rituximab/Bendamustine (RB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab/Bendamustine (RB) followed by Rituximab/High-dose Cytarabine (RC)
Study: 26729653
Drug: Various immunosuppressants
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various immunosuppressants
Study: 26731755
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical cidofovir cream applied intraanally three times per week for 4 weeks
Study: 26731755
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical cidofovir cream
Study: 26734580
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of sorafenib (400 mg twice daily for 28 days) combined with HAIC using CDDP (20 mg/m(2) on days 1 and 8) and 5-FU (330 mg/m(2) continuously on days 1-5 and 8-12) via an implanted catheter system.